Pharma News

Pfizer's Ibrance got accelerated approval from US FDA

  • Posted on: 4 February 2015
  • By: PharmaTutor News

U. S. Food and Drug Administration granted accelerated approval to palbociclib (IBRANCE, Pfizer, Inc.) for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

Arsenic in drinking water tied to drop in breast cancer deaths

  • Posted on: 3 February 2015
  • By: PharmaTutor News

A new study has found that high levels of arsenic in drinking water were associated with an "astonishing" 50 per cent drop in breast cancer deaths in Chile. The study presents results of breast cancer mortality data from a region in Chile where residents were inadvertently exposed to high levels of arsenic, a naturally occurring element found in many minerals.

Now a Phone sniffs out disease

  • Posted on: 3 February 2015
  • By: PharmaTutor News

A research consortium headed by Professor Hossam Haick of the Technion-Israel Institute of Technology is developing a product that, when coupled with a smartphone, will be able to screen the user’s breath for early detection of life-threatening diseases.

National Level Workshop on Industrial and Academic Perspectives of Regulatory Affairs to be held at Ali Allana College of Pharmacy, Akkalkuwa, Nandurbar

  • Posted on: 3 February 2015
  • By: PharmaTutor News

Jamia Islamia Isha Atul Uloom’s Ali Allana College of Pharmacy, Akkalkuwa, Dist. Nandurbar has organized national level workshop on “Industrial and Academic Perspectives of Regulatory Affairs in pharmaceutical industry.” This will be one day workshop on 10 February 2015 from time 10 am to 4.30 pm.

Jakavi found superior to standard therapy for Polycythemia Vera

  • Posted on: 29 January 2015
  • By: PharmaTutor News

Novartis announced results from the pivotal Phase III clinical trial demonstrating Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy (a procedure to remove blood from the body to reduce the concentration of red blood cells) and reduced spleen size in patients with polycythemia vera (PV) who had an inadequate response to or unacceptable side effects from hydroxyurea as defined according to the modified European LeukemiaNet (ELN) criteria, which is published in The New England Journal of Medicine (NEJM). In PV, hematocrit control and spleen size reduction are key measures of a patient's response to therapy.

Cholera bacterium kills other bacteria to steal their dna

  • Posted on: 29 January 2015
  • By: PharmaTutor News

Scientists have discovered the unconventional way the cholera bacterium stabs and kills other bacteria to steal their DNA, making it potentially more virulent. Cholera is caused when the bacterium Vibrio cholerae (V cholerae) infects the small intestine. The disease is characterised by acute watery diarrhea resulting in severe dehydration.

Pages